Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fox

Showing results (1281-1290 of 1,511) with videos related to

Pageof 152
Sort By:
Hippocampus|December 10, 2016
White matter hyperintensities are associated with disproportionate progressive hippocampal atrophyCassidy M Fiford, Emily N Manning, Jonathan W Bartlett, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 26, 2021
Subjective cognitive complaints at age 70: associations with amyloid and mental healthIvanna M Pavisic, Kirsty Lu, Sarah E Keuss, et al.
Neuroimage|December 8, 2007
Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coilsRichard G Boyes, Jeff L Gunter, Chris Frost, et al.
Lancet (London, England)|September 25, 2025
Alzheimer's disease outlook: controversies and future directionsGiovanni B Frisoni, Emil Aho, Carol Brayne, et al.
Brain Communications|February 3, 2025
The relationship between leisure time physical activity patterns, Alzheimer's disease markers and cognitionSarah-Naomi James, Carole H Sudre, Josephine Barnes, et al.
Neurology|October 27, 2017
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegenerationPhilip S J Weston, Teresa Poole, Natalie S Ryan, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
European Journal of Endocrinology|April 29, 2025
Sex differences between mid-life glycaemic traits and brain volume at age 70: a population-based studyNasri Fatih, Alun Hughes, Carole H Sudre, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
Pageof 152

Showing results (1281-1290 of 1,511) with videos related to

Sort By:
Pageof 152
Hippocampus|December 10, 2016
White matter hyperintensities are associated with disproportionate progressive hippocampal atrophyCassidy M Fiford, Emily N Manning, Jonathan W Bartlett, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 26, 2021
Subjective cognitive complaints at age 70: associations with amyloid and mental healthIvanna M Pavisic, Kirsty Lu, Sarah E Keuss, et al.
Neuroimage|December 8, 2007
Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coilsRichard G Boyes, Jeff L Gunter, Chris Frost, et al.
Lancet (London, England)|September 25, 2025
Alzheimer's disease outlook: controversies and future directionsGiovanni B Frisoni, Emil Aho, Carol Brayne, et al.
Brain Communications|February 3, 2025
The relationship between leisure time physical activity patterns, Alzheimer's disease markers and cognitionSarah-Naomi James, Carole H Sudre, Josephine Barnes, et al.
Neurology|October 27, 2017
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegenerationPhilip S J Weston, Teresa Poole, Natalie S Ryan, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
European Journal of Endocrinology|April 29, 2025
Sex differences between mid-life glycaemic traits and brain volume at age 70: a population-based studyNasri Fatih, Alun Hughes, Carole H Sudre, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
Pageof 152